了解激素受体阳性乳腺癌对他莫昔芬的耐药性。 - Suppr

Suppr

超能文献

Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.

作者信息

Higgins Michaela J, Stearns Vered

机构信息

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231-1000, USA.

出版信息

Clin Chem. 2009 Aug;55(8):1453-5. doi: 10.1373/clinchem.2009.125377. Epub 2009 Jun 18.

DOI:10.1373/clinchem.2009.125377

PMID:19541862

Abstract

摘要

相似文献

Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.

Clin Chem. 2009 Aug;55(8):1453-5. doi: 10.1373/clinchem.2009.125377. Epub 2009 Jun 18.

Modification of tamoxifen response: what have we learned?

J Clin Oncol. 2008 Apr 1;26(10):1764-5; author reply 1765-6. doi: 10.1200/JCO.2007.15.5432.

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.

Clin Adv Hematol Oncol. 2008 Nov;6(11):825-33.

Update on CYP2D6 and its impact on tamoxifen therapy.

Clin Adv Hematol Oncol. 2010 Aug;8(8):536-8.

Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?

Expert Rev Anticancer Ther. 2011 Feb;11(2):185-93. doi: 10.1586/era.10.228.

The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen.

Oncogene. 2020 Oct;39(40):6300-6312. doi: 10.1038/s41388-020-01435-4. Epub 2020 Aug 25.

A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?

J Natl Cancer Inst. 2008 May 7;100(9):610-3. doi: 10.1093/jnci/djn127. Epub 2008 Apr 29.

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies.

J Natl Cancer Inst. 2015 Jan 31;107(2). doi: 10.1093/jnci/dju437. Print 2015 Feb.

PharmGKB summary: tamoxifen pathway, pharmacokinetics.

Pharmacogenet Genomics. 2013 Nov;23(11):643-7. doi: 10.1097/FPC.0b013e3283656bc1.

Tamoxifen benefits and CYP2D6 testing in women with hormone receptor-positive breast cancer.

Clin J Oncol Nurs. 2013 Apr;17(2):174-9. doi: 10.1188/13.CJON.174-179.

引用本文的文献

Unveiling role of oncogenic signalling pathways in complicating breast cancer.

Biomedicine (Taipei). 2025 Mar 1;15(1):13-21. doi: 10.37796/2211-8039.1640. eCollection 2025.

Targeting the PI3K Pathway: Advancements and Achievements in Breast Cancer Therapy.

Curr Pharm Des. 2025;31(31):2481-2503. doi: 10.2174/0113816128357976250122042633.

Polyphenols as Immunomodulators and Epigenetic Modulators: An Analysis of Their Role in the Treatment and Prevention of Breast Cancer.

Nutrients. 2024 Nov 29;16(23):4143. doi: 10.3390/nu16234143.

Monkey king evolution (MKE)-GA-SVM model for subtype classification of breast cancer.

Digit Health. 2024 Dec 10;10:20552076241297002. doi: 10.1177/20552076241297002. eCollection 2024 Jan-Dec.

Bazedoxifene as a Potential Cancer Therapeutic Agent Targeting IL-6/GP130 Signaling.

Curr Oncol. 2024 Sep 25;31(10):5737-5751. doi: 10.3390/curroncol31100426.

Navigating heme pathways: the breach of heme oxygenase and hemin in breast cancer.

Mol Cell Biochem. 2025 Mar;480(3):1495-1518. doi: 10.1007/s11010-024-05119-5. Epub 2024 Sep 17.

DCTPP1 Expression as a Predictor of Chemotherapy Response in Luminal A Breast Cancer Patients.

Biomedicines. 2024 Aug 2;12(8):1732. doi: 10.3390/biomedicines12081732.

Identifying prognostic subgroups of luminal-A breast cancer using deep autoencoders and gene expressions.

PLoS Comput Biol. 2023 May 30;19(5):e1011197. doi: 10.1371/journal.pcbi.1011197. eCollection 2023 May.

The obesity-breast cancer link: a multidisciplinary perspective.

Cancer Metastasis Rev. 2022 Sep;41(3):607-625. doi: 10.1007/s10555-022-10043-5. Epub 2022 Jun 25.

A review of the endocrine resistance in hormone-positive breast cancer.

Am J Cancer Res. 2021 Aug 15;11(8):3813-3831. eCollection 2021.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.

作者信息

Higgins Michaela J, Stearns Vered

机构信息

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21231-1000, USA.

出版信息

Clin Chem. 2009 Aug;55(8):1453-5. doi: 10.1373/clinchem.2009.125377. Epub 2009 Jun 18.

DOI:10.1373/clinchem.2009.125377

PMID:19541862

Abstract

摘要

相似文献

Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.

Clin Chem. 2009 Aug;55(8):1453-5. doi: 10.1373/clinchem.2009.125377. Epub 2009 Jun 18.

Modification of tamoxifen response: what have we learned?

J Clin Oncol. 2008 Apr 1;26(10):1764-5; author reply 1765-6. doi: 10.1200/JCO.2007.15.5432.

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.

Clin Adv Hematol Oncol. 2008 Nov;6(11):825-33.

Update on CYP2D6 and its impact on tamoxifen therapy.

Clin Adv Hematol Oncol. 2010 Aug;8(8):536-8.

Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?

Expert Rev Anticancer Ther. 2011 Feb;11(2):185-93. doi: 10.1586/era.10.228.

The proapoptotic gene interferon regulatory factor-1 mediates the antiproliferative outcome of paired box 2 gene and tamoxifen.

Oncogene. 2020 Oct;39(40):6300-6312. doi: 10.1038/s41388-020-01435-4. Epub 2020 Aug 25.

A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?

J Natl Cancer Inst. 2008 May 7;100(9):610-3. doi: 10.1093/jnci/djn127. Epub 2008 Apr 29.

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for tamoxifen pharmacogenetic studies.

J Natl Cancer Inst. 2015 Jan 31;107(2). doi: 10.1093/jnci/dju437. Print 2015 Feb.

PharmGKB summary: tamoxifen pathway, pharmacokinetics.

Pharmacogenet Genomics. 2013 Nov;23(11):643-7. doi: 10.1097/FPC.0b013e3283656bc1.

Tamoxifen benefits and CYP2D6 testing in women with hormone receptor-positive breast cancer.

Clin J Oncol Nurs. 2013 Apr;17(2):174-9. doi: 10.1188/13.CJON.174-179.

引用本文的文献

Unveiling role of oncogenic signalling pathways in complicating breast cancer.

Biomedicine (Taipei). 2025 Mar 1;15(1):13-21. doi: 10.37796/2211-8039.1640. eCollection 2025.

Targeting the PI3K Pathway: Advancements and Achievements in Breast Cancer Therapy.

Curr Pharm Des. 2025;31(31):2481-2503. doi: 10.2174/0113816128357976250122042633.

Polyphenols as Immunomodulators and Epigenetic Modulators: An Analysis of Their Role in the Treatment and Prevention of Breast Cancer.

Nutrients. 2024 Nov 29;16(23):4143. doi: 10.3390/nu16234143.

Monkey king evolution (MKE)-GA-SVM model for subtype classification of breast cancer.

Digit Health. 2024 Dec 10;10:20552076241297002. doi: 10.1177/20552076241297002. eCollection 2024 Jan-Dec.

Bazedoxifene as a Potential Cancer Therapeutic Agent Targeting IL-6/GP130 Signaling.

Curr Oncol. 2024 Sep 25;31(10):5737-5751. doi: 10.3390/curroncol31100426.

Navigating heme pathways: the breach of heme oxygenase and hemin in breast cancer.

Mol Cell Biochem. 2025 Mar;480(3):1495-1518. doi: 10.1007/s11010-024-05119-5. Epub 2024 Sep 17.

DCTPP1 Expression as a Predictor of Chemotherapy Response in Luminal A Breast Cancer Patients.

Biomedicines. 2024 Aug 2;12(8):1732. doi: 10.3390/biomedicines12081732.

Identifying prognostic subgroups of luminal-A breast cancer using deep autoencoders and gene expressions.

PLoS Comput Biol. 2023 May 30;19(5):e1011197. doi: 10.1371/journal.pcbi.1011197. eCollection 2023 May.

The obesity-breast cancer link: a multidisciplinary perspective.

Cancer Metastasis Rev. 2022 Sep;41(3):607-625. doi: 10.1007/s10555-022-10043-5. Epub 2022 Jun 25.

A review of the endocrine resistance in hormone-positive breast cancer.

Am J Cancer Res. 2021 Aug 15;11(8):3813-3831. eCollection 2021.